First-to-patent does not predict first- or best-in-class: analysis of approved small molecule vs. biologic drugs.
The biopharmaceutical enterprise continues to analyze, refine, and identify key strategic factors predicting success of innovative therapeutic advances to address important unmet medical needs. A key comparison has focused on the relative benefits of the novel mechanism of a first-in-class drug vs. the superior properties that differentiate improved follow-on drugs (best-in-class). A corollary question to first-in-class vs. best-in-class is the impact of patent timing. Surprisingly, first-to-patent does not predict first- or best-in-class.